INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Hims & Hers Health Inc. to Contact Law Firm
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) S...
Italy set to speed through $2.3 billion Novo Nordisk investment
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.
Novo Nordisk's Sell-Off Has Gone Too Far
Novo Nordisk's recent sell-off is overdone; current fears around pricing and CagriSema are temporary, creating a compelling buying opportunity. The company's fundamentals remain strong, with robust...
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerab...
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stoc...
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based ...
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Lea...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novo Nordisk A/S (“Nov...
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Com...
Novo Nordisk launches blockuster weight-loss drug Wegovy in India
Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week injection in India.
Related Companies